التفاصيل البيبلوغرافية
| العنوان: |
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study |
| المؤلفون: |
Tivey, Ann, Shotton, Rohan, Eyre, Toby A., Lewis, David, Stanton, Louise, Allchin, Rebecca, Walter, Harriet, Miall, Fiona, Zhao, Rui, Santarsieri, Anna, McCulloch, Rory, Bishton, Mark, Beech, Amy, Willimott, Victoria, Fowler, Nicole, Bedford, Claudia, Goddard, Jack, Protheroe, Sam, Everden, Angharad, Tucker, David, Wright, Josh, Dukka, Vasavi, Reeve, Miriam, Paneesha, Shankara, Prahladan, Mahesh, Hodson, Andrew, Qureshi, Iman, Koppana, Manasvi, Owen, Mary, Ediriwickrema, Kushani, Marr, Helen, Wilson, Jamie, Lambert, Jonathan, Wrench, David, Burney, Claire, Knott, Chloe, Talbot, Georgina, Gibb, Adam, Lord, Angela, Jackson, Barry, Stern, Simon, Sutton, Taylor, Webb, Amy, Wilson, Marketa, Thomas, Nicky, Norman, Jane, Davies, Elizabeth, Lowry, Lisa, Maddox, Jamie, Phillips, Neil, Crosbie, Nicola, Flont, Marcin, Nga, Emma, Virchis, Andres, Camacho, Raisa Guerrero, Swe, Wunna, Pillai, Arvind, Rees, Clare, Bailey, James, Jones, Steve, Smith, Susan, Sharpley, Faye, Hildyard, Catherine, Mohamedbhai, Sajir, Nicholson, Toby, Moule, Simon, Chaturvedi, Anshuman, Linton, Kim |
| المصدر: |
Blood Advances; 20240101, Issue: Preprints |
| مستخلص: |
•Ibrutinib ± rituximab was effective and well tolerated as first-line MCL therapy; outcomes were worse in patients with high-risk disease.•Novel approaches are needed for patients with high-risk MCL and those with progressive disease after first-line ibrutinib. |
| قاعدة البيانات: |
Supplemental Index |
Full Text via ClinicalKey 
Full Text Finder 